Keep up to speed with the sector’s top executive appointments with DDW’s regular recruitment round-up.
Kimryn Rathmell has been chosen as the 17th director of the National Cancer Institute (NCI), bringing her experience as leader of the Department of Medicine at the Vanderbilt University Medical Center and Physician-in-Chief at the Vanderbilt University Adult Hospital and Clinics.
Genomics company Broken String Biosciences has expanded its senior leadership team with the appointments of Vincent Smith as Chief Technology Officer, Jessica Rich as VP Business Development, and Gavin Burns as Vice President of Quality and Operations.
FUJIFILM Diosynth Biotechnologies has appointed Maja Pedersen as Chief Quality Officer (CQO). Pedersen returns to FUJIFILM from Biogen where she most recently served as the Global Head of External Manufacturing.
Konstantinos Vlassis has joined TechBio Closed Loop Medicine as Chief Technology Officer (CTO) and will oversee the management of the company’s technology platforms.
Organ-on-a-chip company CN Bio has appointed Neil Rumbelow as Director of Product Development, and who joins CN Bio from Owlstone Medical where he was Head of Engineering.
Enhanc3D Genomics has appointed Hazel Jones as its new Chief Operating Officer. Jones has over 10 years of senior leadership experience in oncology research and was most recently Executive Product Director of Clinical Data at AstraZeneca.
Business development expert Andrew Dunn will establish and lead Quantum Brilliance’s new UK office. He joins Quantum Brilliance by way of Arm Holdings, Cambridge, UK; Royal Bank of Canada, London; the Royal Society, London; University of Nottingham; and TU Delft.
Anthony Johnson has joined the Board of synthetic biology company NanoSyrinx as a Non-Executive Director. Most recently, Johnson held the position of Chief Executive Officer at Goldfinch Bio and is Chair of the Board of Directors at Outrun Therapeutics.
Jedd Comiskey has been announced as the new Senior VP – Head of Europe at Outlook Therapeutics, bringing a successful track record in the planning, organisation and execution of product launches.
Cell and gene therapy developer eXmoor pharma has hired Matthew Paterson as the company’s first Chief Commercial Officer, moving on from 18 years at Quotient Sciences.
Thierry Van Nieuwenhove has become the new Chief Executive Officer (CEO) for Quotient Sciences, succeeding Mark Egerton, who is retiring. Wayne Hewett has been appointed as Non-Executive Chairman.
Ori Biotech has appointed Gillian Bonthron as Chief Financial Officer and John Machulski, previously at Catalent, as Chief Operating Officer, while Thomas Heathman has been promoted to Chief Commercial Officer.
The new Chairman of the Board at Astraveus will be Michel Spagnol, former CEO and Chairman of Novasep, an international CDMO group based in France.
Fibrocor Therapeutics has announced the additions of William Newsome III as President and Chief Executive Officer and Piet Wigerinck as Chief Scientific Advisor. Newsome was one of the co-founders of Fibrocor when he was at Evotec.
Professor Charlotte Deane MBE is the new Executive Chair of the Engineering & Physical Sciences Research Council (EPSRC). She is currently Professor of Structural Bioinformatics at the University of Oxford and Chief AI Officer at Exscientia.
Jérôme Martinez has moved to ABIONYX Pharma as Senior Advisor from a position as COO in France for pharmaceutical company SANTEN, specialising in ophthalmology and rheumatology.
Diana Spencer, Senior Digital Content Editor, DDW